Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
Ann Neurol
    October 2022
  1. GOTTESMAN RF, Wu A, Coresh J, Knopman DS, et al
    Associations of Vascular Risk and Amyloid Burden with Subsequent Dementia.
    Ann Neurol. 2022;92:607-619.
    >> Share

    September 2022
  2. JOSEPH-MATHURIN N, Llibre-Guerra JJ, Li Y, McCullough AA, et al
    Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease.
    Ann Neurol. 2022 Sep 24. doi: 10.1002/ana.26511.
    >> Share

  3. CASULA EP, Borghi I, Maiella M, Pellicciari MC, et al
    Regional precuneus cortical hyperexcitability in Alzheimer's disease patients.
    Ann Neurol. 2022 Sep 22. doi: 10.1002/ana.26514.
    >> Share

  4. JOH HK, Kwon H, Son KY, Yun JM, et al
    Allergic diseases and risk of incident dementia and Alzheimer's disease.
    Ann Neurol. 2022 Sep 12. doi: 10.1002/ana.26506.
    >> Share

  5. LAN G, Cai Y, Li A, Liu Z, et al
    Association of presynaptic loss with Alzheimer's disease and cognitive decline.
    Ann Neurol. 2022 Sep 3. doi: 10.1002/ana.26492.
    >> Share

  6. HU H, Bi YL, Shen XN, Ma YH, et al
    Application of the Amyloid/Tau/Neurodegeneration Framework in Cognitively Intact Adults: The CABLE Study.
    Ann Neurol. 2022;92:439-450.
    >> Share

  7. SMIRNOV DS, Salmon DP, Galasko D, Edland SD, et al
    TDP-43 Pathology Exacerbates Cognitive Decline in Primary Age-Related Tauopathy.
    Ann Neurol. 2022;92:425-438.
    >> Share

  8. BACHMANN D, Roman ZJ, Buchmann A, Zuber I, et al
    Lifestyle Affects Amyloid Burden and Cognition Differently in Men and Women.
    Ann Neurol. 2022;92:451-463.
    >> Share

    August 2022
  9. AL-MUBARAK B, Ahmed Nour M, Schumacher-Schuh A, Bandres-Ciga S, et al
    Globalizing research towards diverse representation in Alzheimer's and Parkinson's disease.
    Ann Neurol. 2022 Aug 24. doi: 10.1002/ana.26483.
    >> Share

  10. JOSEPHS KA, Tosakulwong N, Gatto RG, Weigand SD, et al
    Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross-Sectional Tau Positron Emission Tomography.
    Ann Neurol. 2022 Aug 15. doi: 10.1002/ana.26479.
    >> Share

  11. RAUCHMANN BS, Brendel M, Franzmeier N, Trappmann L, et al
    Microglial Activation and Connectivity in Alzheimer Disease and Aging.
    Ann Neurol. 2022 Aug 1. doi: 10.1002/ana.26465.
    >> Share

    July 2022
  12. SUN L, Guo D, Jia Y, Shi M, et al
    Association Between Human Blood Metabolome and the Risk of Alzheimer's Disease.
    Ann Neurol. 2022 Jul 28. doi: 10.1002/ana.26464.
    >> Share

  13. HEAD E, Zetterberg H
    Commentary on Oeckl et al., "Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181".
    Ann Neurol. 2022;92:3-5.
    >> Share

  14. OECKL P, Wagemann O, Halbgebauer S, Anderl-Straub S, et al
    Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181.
    Ann Neurol. 2022;92:6-10.
    >> Share

    June 2022
  15. CASULA EP, Pellicciari MC, Bonni S, Borghi I, et al
    Decreased frontal gamma activity in Alzheimer's disease patients.
    Ann Neurol. 2022 Jun 17. doi: 10.1002/ana.26444.
    >> Share

  16. SCHINDLER SE, Ney DE, Goss AL, Rabinovici G, et al
    ANA Investigates: The Future of Biomarkers in Alzheimer Disease.
    Ann Neurol. 2022 Jun 11. doi: 10.1002/ana.26437.
    >> Share

  17. CORNELIS MC, Bennett DA, Weintraub S, Schneider JA, et al
    Caffeine Consumption and Dementia: Are Lewy Bodies the Link?
    Ann Neurol. 2022;91:834-846.
    >> Share

  18. GRATUZE M, Jiang H, Wang C, Xiong M, et al
    APOE Antibody Inhibits Abeta-Associated Tau Seeding and Spreading in a Mouse Model.
    Ann Neurol. 2022;91:847-852.
    >> Share

    May 2022
  19. BENUSSI A, Cantoni V, Grassi M, Brechet L, et al
    Increasing brain gamma activity improves episodic memory and restores cholinergic dysfunction in Alzheimer's disease.
    Ann Neurol. 2022 May 24. doi: 10.1002/ana.26411.
    >> Share

  20. GANDY S
    A Letter Concerning "Aducanumab: What about the Patient?"
    Ann Neurol. 2022;91:732-733.
    >> Share

    April 2022
  21. BUCKLEY RF, O'Donnell A, McGrath ER, Jacobs HIL, et al
    Menopause status moderates sex differences in tau burden: a Framingham PET Study.
    Ann Neurol. 2022 Apr 26. doi: 10.1002/ana.26382.
    >> Share

    March 2022
  22. LEE YG, Jeon S, Park M, Kang SW, et al
    Effects of Alzheimer's and Lewy Body Disease Pathologies on Brain Metabolism.
    Ann Neurol. 2022 Mar 21. doi: 10.1002/ana.26355.
    >> Share

  23. BENITEZ A, Jensen JH, Thorn K, Dhiman S, et al
    Greater diffusion restriction in white matter in Preclinical Alzheimer's disease.
    Ann Neurol. 2022 Mar 13. doi: 10.1002/ana.26353.
    >> Share

    January 2022
  24. MEYER PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, et al
    Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.
    Ann Neurol. 2022 Jan 27. doi: 10.1002/ana.26308.
    >> Share

    October 2021
  25. SANDROCK A
    Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius.
    Ann Neurol. 2021 Oct 23. doi: 10.1002/ana.26254.
    >> Share

  26. DAS SR, Lyu X, Duong MT, Xie L, et al
    Tau-atrophy variability reveals phenotypic heterogeneity in Alzheimer's disease.
    Ann Neurol. 2021 Oct 7. doi: 10.1002/ana.26233.
    >> Share

    September 2021
  27. PETERSEN RC
    Aducanumab: What about the Patient?
    Ann Neurol. 2021;90:334-335.
    >> Share

    July 2021
  28. TAN EK
    Genetic studies of Parkinson's & Alzheimer's disease in Latinos/Hispanics: New Insights & Challenges.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26179.
    >> Share

  29. MONTAL V, Barroeta I, Bejanin A, Pegueroles J, et al
    Metabolite signature of Alzheimer's disease in adults with Down syndrome.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26178.
    >> Share

  30. DAUTRICOURT S, de Flores R, Landeau B, Poisnel G, et al
    Longitudinal changes in hippocampal network connectivity in Alzheimer's disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26168.
    >> Share

  31. MOGHAVEM N, Henderson VW, Greicius MD
    Medicare should not cover aducanumab as a treatment for Alzheimer's disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26167.
    >> Share

    May 2021
  32. LIN BSZ, Sur S, Liu P, Li Y, et al
    Blood-brain barrier breakdown in relationship to Alzheimer and vascular disease.
    Ann Neurol. 2021 May 26. doi: 10.1002/ana.26134.
    >> Share

  33. SARIYA S, Felsky D, Reyes-Dumeyer D, Lali R, et al
    Polygenic risk score for Alzheimer's Disease in Caribbean Hispanics.
    Ann Neurol. 2021 May 26. doi: 10.1002/ana.26131.
    >> Share

    April 2021
  34. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    >> Share

    March 2021
  35. PETERSEN RC, Wiste HJ, Weigand SD, Fields JA, et al
    NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages.
    Ann Neurol. 2021 Mar 26. doi: 10.1002/ana.26071.
    >> Share

  36. BUCIUC M, Whitwell JL, Kasanuki K, Graff-Radford J, et al
    Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype.
    Ann Neurol. 2021;89:520-533.
    >> Share

    February 2021
  37. KONIJNENBERG E, Tomassen J, den Braber A, Ten Kate M, et al
    The onset of preclinical Alzheimer's disease in monozygotic twins.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26048.
    >> Share

  38. FILIPPONE A, Pratico D
    Endosome dysregulation in Down syndrome: a potential contributor to Alzheimer's disease pathology.
    Ann Neurol. 2021 Feb 6. doi: 10.1002/ana.26042.
    >> Share

  39. MEEKER KL, Wisch JK, Hudson D, Coble D, et al
    Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework.
    Ann Neurol. 2021;89:254-265.
    >> Share

    December 2020
  40. RAJAN KB, Aggarwal NT, McAninch EA, Weuve J, et al
    Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study.
    Ann Neurol. 2020;88:1065-1076.
    >> Share

    November 2020
  41. LESMAN-SEGEV OH, La Joie R, Iaccarino L, Lobach I, et al
    Diagnostic Accuracy of Amyloid versus FDG PET in Autopsy-Confirmed Dementia.
    Ann Neurol. 2020 Nov 20. doi: 10.1002/ana.25968.
    >> Share

  42. BUCKLEY RF, Scott MR, Jacobs HIL, Schultz AP, et al
    Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline.
    Ann Neurol. 2020;88:921-932.
    >> Share

    October 2020
  43. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25947.
    >> Share

  44. MOUSSA C
    Reply to Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25946.
    >> Share

  45. NOYCE AJ, Klein C
    Genetic risk of Alzheimer's disease - Sleepless with the enemy.
    Ann Neurol. 2020 Oct 18. doi: 10.1002/ana.25938.
    >> Share

  46. ESPAY AJ, Marsili L, Mahajan A, Sturchio A, et al
    Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25923.
    >> Share

    September 2020
  47. ANDREWS SJ, Fulton-Howard B, O'Reilly P, Marcora E, et al
    Causal associations between modifiable risk factors and the Alzheimer's phenome.
    Ann Neurol. 2020 Sep 29. doi: 10.1002/ana.25918.
    >> Share

  48. LENG Y, Ackley SF, Glymour MM, Yaffe K, et al
    Genetic risk of Alzheimer's disease and sleep duration in non-demented elders.
    Ann Neurol. 2020 Sep 20. doi: 10.1002/ana.25910.
    >> Share

  49. LAO PJ, Gutierrez J, Keator D, Rizvi B, et al
    Alzheimer's-related cerebrovascular disease in Down syndrome.
    Ann Neurol. 2020 Sep 18. doi: 10.1002/ana.25905.
    >> Share

    August 2020
  50. GHIRELLI A, Tosakulwong N, Weigand SD, Clark HM, et al
    Sensitivity-specificity of tau and Abeta PET in frontotemporal lobar degeneration.
    Ann Neurol. 2020 Aug 31. doi: 10.1002/ana.25893.
    >> Share

  51. MENGEL D, Janelidze S, Glynn RJ, Liu W, et al
    Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease.
    Ann Neurol. 2020 Aug 23. doi: 10.1002/ana.25885.
    >> Share

  52. HALPERIN JJ, Pascual-Leone A, Saper CB
    Symptomatic Hydrocephalus with Normal Cerebrospinal Pressure and Alzheimer's Disease.
    Ann Neurol. 2020 Aug 9. doi: 10.1002/ana.25871.
    >> Share

    July 2020
  53. MULLER-SCHMITZ K, Krasavina-Loka N, Yardimci T, Lipka T, et al
    Normal pressure hydrocephalus associated with Alzheimer' disease.
    Ann Neurol. 2020 Jul 13. doi: 10.1002/ana.25847.
    >> Share

  54. NUNEZ C, Callen A, Lombardini F, Compta Y, et al
    Different Cortical Gyrification Patterns in Alzheimer's Disease and Impact on Memory Performance.
    Ann Neurol. 2020;88:67-80.
    >> Share

    June 2020
  55. ARVANITAKIS Z, Wang HY, Capuano AW, Khan A, et al
    Brain insulin signaling, Alzheimer's disease pathology, and cognitive function.
    Ann Neurol. 2020 Jun 18. doi: 10.1002/ana.25826.
    >> Share

  56. IRWIN DJ, Felder J, Coffey CS, Caspell-Garcia C, et al
    Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Ann Neurol. 2020 Jun 16. doi: 10.1002/ana.25811.
    >> Share

  57. SCARIONI M, Gami-Patel P, Timar Y, Seelaar H, et al
    Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology.
    Ann Neurol. 2020;87:950-961.
    >> Share

  58. BUCKLEY R, Pascual-Leone A
    Age-Related Cognitive Decline Is Indicative of Neuropathology.
    Ann Neurol. 2020;87:813-815.
    >> Share

    May 2020
  59. TURNER RS, Hebron ML, Lawler A, Mundel EE, et al
    Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
    Ann Neurol. 2020 May 28. doi: 10.1002/ana.25775.
    >> Share

  60. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    >> Share

    April 2020
  61. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    >> Share

    March 2020
  62. STRANDBERG TE, Tienari PJ, Kivimaki M
    Vascular and Alzheimer's disease in dementia.
    Ann Neurol. 2020 Mar 10. doi: 10.1002/ana.25715.
    >> Share

    January 2020
  63. ZEYDAN B, Lowe VJ, Reichard RR, Przybelski SA, et al
    Imaging Biomarkers of Alzheimer's Disease in Multiple Sclerosis.
    Ann Neurol. 2020 Jan 22. doi: 10.1002/ana.25684.
    >> Share

  64. DESPA F, Goldstein LB, Biessels GJ
    Amylin as a Potential Link between Type 2 Diabetes and Alzheimer Disease.
    Ann Neurol. 2020 Jan 9. doi: 10.1002/ana.25668.
    >> Share

    November 2019
  65. HANSEEUW BJ, Scott MR, Sikkes S, Properzi M, et al
    Evolution of anosognosia in Alzheimer's disease and its relationship to amyloid.
    Ann Neurol. 2019 Nov 21. doi: 10.1002/ana.25649.
    >> Share

  66. GUSTAVSSON AM, van Westen D, Stomrud E, Engstrom G, et al
    Midlife atherosclerosis and development of Alzheimer's or vascular dementia.
    Ann Neurol. 2019 Nov 12. doi: 10.1002/ana.25645.
    >> Share

  67. WILLIAMS DM, Finan C, Schmidt AF, Burgess S, et al
    Lipid lowering and Alzheimer's disease risk: a Mendelian randomization study.
    Ann Neurol. 2019 Nov 12. doi: 10.1002/ana.25642.
    >> Share

  68. PRINS S, Zhuparris A, Groeneveld GJ
    The Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes depends on the study population.
    Ann Neurol. 2019 Nov 1. doi: 10.1002/ana.25634.
    >> Share

  69. VERBERK IMW, Teunissen CE, Van der Flier WM
    Reply to "The Usefulness of Plasma Amyloid as Prescreener of the earliest Alzheimer Pathological Changes depends on the study population".
    Ann Neurol. 2019 Nov 1. doi: 10.1002/ana.25633.
    >> Share

    October 2019
  70. JAMES BD, Wilson RS, Capuano AW, Boyle PA, et al
    Hospitalization, Alzheimer's and Related Neuropathologies, and Cognitive Decline.
    Ann Neurol. 2019 Oct 15. doi: 10.1002/ana.25621.
    >> Share

    September 2019
  71. MENG Y, Abrahao A, Heyn CC, Bethune AJ, et al
    Glymphatics visualization after focused ultrasound induced blood-brain barrier opening in humans.
    Ann Neurol. 2019 Sep 16. doi: 10.1002/ana.25604.
    >> Share

    August 2019
  72. KUMMER BR, Diaz I, Wu X, Aaroe AE, et al
    Associations between cerebrovascular risk factors and parkinson disease.
    Ann Neurol. 2019 Aug 29. doi: 10.1002/ana.25564.
    >> Share

    July 2019
  73. SCHULTZ A, Kloet RW, Sohrabi HR, van der Weerd L, et al
    Amyloid Imaging of Dutch-type Hereditary Cerebral Amyloid Angiopathy Carriers.
    Ann Neurol. 2019 Jul 30. doi: 10.1002/ana.25560.
    >> Share

    February 2019
  74. COUGHLIN D, Xie SX, Liang M, Williams A, et al
    Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Ann Neurol. 2019;85:259-271.
    >> Share

    January 2019
  75. GABELLE A, Jaussent I, Bouallegue FB, Lehmann S, et al
    Reduced brain amyloid burden in elderly patients with narcolepsy type 1.
    Ann Neurol. 2019;85:74-83.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016